Articles

A novel RADscore based on correlation of radiomic features with clinical outcomes in patients with R/R LBCL receiving CAR-T therapy outperformed conventional PET parameters for prognostication. Read More ›

Year in Review

TRANSFORM Primary Analysis and Indirect Comparison of Liso-cel to Axi-cel

LBCL 2022 - Year in Review

Dr Jeremy S. Abramson analyzes data from the primary analysis of the TRANSFORM study and a matching-adjusted indirect comparison of liso-cel to axi-cel for the second-line treatment of primary refractory or early relapsed LBCL. Read More ›

Year in Review

TRANSFORM Primary Analysis Revealed Improved Outcomes with Liso-cel in the 2L Treatment of Primary Refractory or Early Relapsed LBCL

LBCL 2022 - Year in Review

The primary analysis of the TRANSFORM study comparing liso-cel to standard of care in adults with primary refractory or early relapsed LBCL resulted in achievement of key clinical benefit end points. Read More ›

Year in Review

Indirect Comparison of Liso-cel and Axi-cel for 2L Treatment of R/R LBCL Revealed Comparable Efficacy with Safety Outcomes Favoring Liso-cel

LBCL 2022 - Year in Review

Matching-adjusted indirect comparison of liso-cel to axi-cel utilizing data from the TRANSFORM and ZUMA-7 studies revealed lower odds of key CAR-T‒associated adverse events with liso-cel. Read More ›

Year in Review

YTB323 (Rapcabtagene Autoleucel) in R/R DLBCL After ≥2 Lines of Prior Therapy

LBCL 2022 - Year in Review

Phase 1 results of YTB323 in patients with R/R DLBCL demonstrate durable efficacy with a favorable safety profile, as well as identify the recommended phase 2/3 dose. Read More ›

Year in Review

CIBMTR Registry Analysis Evaluated the Impact of Age on Outcomes in Patients with LBCL Receiving CAR-T Therapy

LBCL 2022 - Year in Review

Data from the CIBMTR registry revealed that advanced age does not impact mortality associated with CAR-T therapy, and that CAR-T therapy is feasible in older adults. Read More ›

Year in Review

Inflammatory Biomarker Clusters May Provide a New Means for Risk Stratification of Patients with LBCL Receiving CAR-T Therapy

LBCL 2022 - Year in Review

Two distinct inflammatory clusters were identified and found to be tightly linked to response and survival of patients with LBCL receiving CAR-T therapy, with validation utilizing an independent cohort. Read More ›

HR-Positive/HER2-Negative Breast Cancer

Analysis of the Randomized STIC CTC Trial in ER-Positive/HER2-Negative Metastatic Breast Cancer: Overall Survival Findings

SABCS 2022

Circulating tumor cell count found to provide utility in treatment selection decision-making. Read More ›

HR-Positive/HER2-Negative Breast Cancer

Elacestrant in Postmenopausal Women with ER-Positive/HER2-Negative Early Breast Cancer: Findings from the SOLTI-1905-ELIPSE Trial

SABCS 2022

Preoperative treatment with elacestrant is associated with relevant biological and molecular responses. Read More ›

HR-Positive/HER2-Negative Breast Cancer

Maintenance Ribociclib and ET Following First-Line Chemotherapy in HR-Positive/HER2-Negative Metastatic Breast Cancer: Findings from the Phase 2 AMICA Trial

SABCS 2022

Ribociclib plus ET shows promising efficacy as maintenance therapy in patients with HR-positive/HER2-negative metastatic breast cancer. Read More ›

Articles

Page 22 of 143